Hypertension Research · Nov 5, 2026

Improved time in therapeutic range and reduced medication burden after renal denervation: a nationwide real-world registry

By Lin CY, Wu LC, Lin PL et al.

The extent to which renal denervation (RDN) improves sustained blood pressure (BP) control, medication burden, and time in therapeutic range (TTR) in real-world Asian populations remains incompletely defined. We analyzed data from a prospective, nationwide, multi-center registry enrolling consecutive hypertensive patients undergoing catheter-based RDN at seven hospitals in Taiwan. Office BP, medication burden, and TTR were assessed over 12 months. Among 142 patients (mean age 59.4 ± 14.7 years; 68.3% men), baseline BP was 155.2 ± 24.1/84.1 ± 14.2 mmHg with a mean medication burden of 2.28 ± 1.19. BP decreased significantly and was sustained throughout follow-up. At 12 months, BP decreased by 13.9 ± 25.2/6.3 ± 20.5 mmHg from baseline (p < 0.01), while medication burden decreased by 0.76 ± 1.26 (p < 0.01). For BP < 140/90 mmHg, TTR increased from 27.7% at baseline to 47.5% at 12 months (p < 0.01); for BP < 130/80 mmHg, TTR increased from 12.8% to 25.9% (p < 0.01). No major procedure-related complications were observed. In this nationwide real-world registry, RDN was associated with durable BP reduction, improved time in therapeutic range, and reduced medication burden over 12 months. These findings suggest that RDN may not only lower BP but also enhance sustained BP control while reducing antihypertensive medication burden in routine clinical practice.

doi.org/10.1038/s41440-026-02803-5PubMed 42988843Interventions

AgingResearch.News